Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Capital Expenditures (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Capital Expenditures data on record, last reported at $88000.0 in Q2 2025.

  • For Q2 2025, Capital Expenditures fell 6.38% year-over-year to $88000.0; the TTM value through Sep 2025 reached $119000.0, up 2280.0%, while the annual FY2024 figure was $268000.0, 1388.89% up from the prior year.
  • Capital Expenditures reached $88000.0 in Q2 2025 per RANI's latest filing, up from $31000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $498000.0 in Q2 2022 and bottomed at -$734000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $51411.8, with a median of $88000.0 recorded in 2025.
  • The widest YoY moves for Capital Expenditures: up 958.62% in 2022, down 428.06% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at -$139000.0 in 2021, then plummeted by 428.06% to -$734000.0 in 2022, then skyrocketed by 68.39% to -$232000.0 in 2023, then skyrocketed by 113.36% to $31000.0 in 2024, then surged by 183.87% to $88000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $88000.0 in Q2 2025, $31000.0 in Q4 2024, and $125000.0 in Q3 2024.